secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2026-06-24T20:15:32+00:00
Accession:  0001104659-26-077306
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 1.02, 3.02, 5.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio agrees to reverse merger with Remix; Remix equity value $226M; $100M concurrent financing
--------------------------------------------------------------------------------

- Remix ascribed equity value of $226M; Passage Bio's equity value ~$20M, subject to net cash adjustment at closing.
- Remix CEO Peter Smith, Ph.D., to lead combined company; Remix will designate all 9 board members.
- Remix stockholders owning ~93% of capital stock signed support agreements to vote in favor; $100M concurrent financing committed.
- Passage Bio terminates Catalent manufacturing agreement and PBFT02 license with Penn, winding down gene therapy programs.
- Passage Bio stockholders receive CVRs for potential proceeds from existing license agreements, but payments not assured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000110465926077306/0001104659-26-077306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000110465926077306/tm2618476d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-077306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer